Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

TSX:AEZS - Post Discussion

COSCIENS Biopharma Inc > Top-line diagnostic results
View:
Post by prophetoffactz on Jun 29, 2024 11:17pm

Top-line diagnostic results

AEZS's pediatric clinical trial completed its last patient last visit 16 days ago with top-line results expected in Q3 2024. 

AEZS's adult clinical trial was completed 2016-11-29 according to clinicaltrials.gov: Study Details | Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency | ClinicalTrials.gov

Top-line results for the adult trial were reported 36 days later in a news release: 2017-01-04 | Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen™ | TSX:AEZS | Press Release (stockhouse.com)

The 36 days to report the top-line adult clinical trial results may have been complicated by Christmas and New Year's holidays.

Assuming it takes 30-36 days to report the pediatric top-line results, given that it has been 16 days since the last patient last visit, it may be possible that we see the top-line results for the pediatric trial in 2-3 weeks. That puts it potentially right around the time of the AGM on July 16, 2024.  
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities